StreetAlpha.app
Home › Stocks › ORIC

Oric Pharmaceuticals, Inc. (ORIC)

Healthcare
$8.00
▲ +6.38%
LAST CLOSE · NOV 17

ORIC Pharmaceuticals develops cancer drug candidates in South San Francisco, led by rinzimetostat for prostate cancer and enozertinib for lung cancer. It last closed at $8.00 on Nov 17, up 6.38% on the day. The average 12-month price target from 5 analysts is $22.00 (+175.0% from the last close), with a high of $26.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ORIC, 0% of them bullish and 100% bearish.

AI Auto Pilots
Is ORIC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$155.8M
EPS (diluted)
−$1.44
Free cash flow
−$129.2M
Valuation
Market cap
$831.5M
103.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$33.8M
At Sep 30
Shareholder equity
$339.5M
Shares outstanding
103.9M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$78.7M−$78.7MFY2021FY2022: −$89.1M−$89.1MFY2022FY2023: −$100.7M−$100.7MFY2023FY2024: −$127.8M−$127.8MFY2024FY2025: −$129.5M−$129.5MFY2025

From ORIC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on ORIC in the past 90 days
Average 12-month target
$22.00
▲ 175.0% upside

Based on 5 analysts who set a price target on ORIC in the past 90 days. The average target is $22.00, with a high of $26.00 and a low of $14.00, compared with the last close of $8.00.

Low $14.00Avg $22.00High $26.00
Blue marker: last close $8.00
Highest target$26.00
Average target$22.00
Lowest target$14.00
Latest rating changes
BTIGReiterated
Nov 17Buy$26
BTIGReiterated
Oct 28Buy$26
WedbushMaintained
Oct 27Buy$14
StifelMaintained
Oct 26Buy$18
JP MorganMaintained
Oct 14Buy$26
DateFirmActionRatingPrice target
Nov 17BTIGReiteratedBuy$26
Oct 28BTIGReiteratedBuy$26
Oct 27WedbushMaintainedBuy$14
Oct 26StifelMaintainedBuy$18
Oct 14JP MorganMaintainedBuy$26
Loading…

Technical Analysis

ORIC · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 19% below its 20 day and 42% below its 50 day average. It is 37% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot at $7.86, and the nearest resistance the Pivot R1 at $8.15.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.7%/day
Key levels
$14.6852 week high+83.5%
$11.80100 day average+47.5%
$11.3650 day average+42.0%
$10.97200 day average+37.1%
$9.5220 day average+19.0%
$8.50Swing high (Jun 10)+6.3%
$8.15Pivot R1+1.9%
$8.00Last close
$7.86Pivot−1.7%
$7.72Pivot S1−3.5%
$7.32Swing low (Jun 3)−8.5%
$7.2352 week low−9.6%
Indicators
RSI (14)34.91Weak, oversold below 30Neutral
MACD-1.04Below its signal lineBearish
Stochastic6.9Near the bottom of its rangeOversold
ADX (14)29.0Trending down
Williams %R-80.9Oversold below −80, overbought above −20Oversold
CCI (20)-93.4Oversold below −100, overbought above 100Neutral
Rate of change−16.6%Change over 10 sessionsBearish
ATR (14)$0.77Typical daily range, 9.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ORIC

What happened before

See how ORIC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ORIC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ORIC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Sep 30 – Sep 30
Loading…

See today’s whale options flow across the market →

ORIC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲116 buying vs 75 selling
  • ▼Held by funds -4.8 pts
  • ▲Funds holding +22
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding203181+12.2%
In funds' top 1098+12.5%
Held by funds114.1%118.9%−4.8 pts
New / increased42 / 7429 / 82+4.5%
Reduced / sold out56 / 1942 / 30+4.2%
Put/call ratio0.040.11−63.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ORIC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ORIC is in one of them and how their past ORIC trades turned out.

ORIC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ORIC in an article yet. Here's the latest on the wider market.

About Oric Pharmaceuticals

ORIC Pharmaceuticals is a biopharmaceutical company based in South San Francisco, California, that develops cancer treatments designed to counter drug resistance. Its two lead candidates are rinzimetostat, which is being studied in advanced prostate cancer, and enozertinib, which is being studied in lung cancer with certain EGFR gene mutations. Neither candidate has been approved for sale yet.

Headquarters
South San Francisco, CA